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Calcitriol ointment has been approved for the treatment
of psoriasis in many countries around the world. It may
be prescribed in conjunction with phototherapy. Our
purpose was to evaluate the e¡ect of various therapeutic
ultraviolet modalities on the stability of calcitriol and,
conversely, to study the e¡ects of calcitriol ointment
on transmission of di¡erent forms of ultraviolet light.
Calcitriol ointment 3 lg per g was irradiated with 10 J
per cm2 ultraviolet A, 100 mJ per cm2 broadband ultra-
violet B, and 3.0 J per cm2 narrowband ultraviolet B,
and its stability was compared with samples exposed
to £uorescent light and ambient sunlight. Ultraviolet A
and ultraviolet B transmission were measured through
thin and thick layers of calcitriol 3 lg per g ointment
and vehicle. More than 90% of calcitriol ointment is
degraded upon exposure to ultraviolet A, broadband ul-
traviolet B, and narrowband ultraviolet B. Transmission
of ultraviolet A is reduced through calcitriol ointment
and its vehicle by 17%^31% and 17%^41%, respectively.
Transmission of ultraviolet B is reduced by 67%^87%
through vehicle and 50%^83% through calcitriol oint-
ment. When used in conjunction with phototherapy,
calcitriol ointment should be applied after ultraviolet
exposure, not before. Calcipotriene, the only vitamin
D analog already approved for psoriasis in the USA,
has been used successfully in combination with ultra-
violet B and psoralen plus ultraviolet A. Key words:
phototherapy/ultraviolet A/ultraviolet B/vitamin D3 analog.
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C
alcitriol ointment has been approved for the treat-
ment of psoriasis in many countries around the
world, and it is rapidly emerging as a new topical
therapy. Three double-blind, randomized, vehicle-
controlled trials have recently been reported
(Langner et al, 2001). Calcipotriene, the only vitamin D analog
already approved for psoriasis in the USA, has been used success-
fully in combination with ultraviolet B (UVB) and psoralen plus
UVA (PUVA) (Hecker and Lebwohl, 1997; Speight & Farr, 1994).
In those studies, calcipotriene ointment was applied after treat-
ment with phototherapy, as UVA has been shown to degrade cal-
cipotriene (Lebwohl et al, 1997). Several other studies have
suggested that calcipotriene ointment blocks UV light (Marsico
and Dijkstra, 1996;Youn et al, 1997; De Rie et al, 2000).
Work conducted with other vitamin D analogs has shown sig-
ni¢cant interactions with UV light (Lebwohl et al, 1997). UVA, at
15^22 J per cm2, reduced calcipotriene concentrations by 2%^75%,
with a mean reduction of 28%. UVB in doses of 100^150 mJ
per cm2 in the latter study did not reduce the concentration of
calcipotriene, but, using an in vitro model, narrowband UVB in
doses ranging from 250 to 1000 mJ per cm2 resulted in dose-de-
pendent decreases in the concentration of 25-hydroxyvitamin D3
and 1,25-dihydroxyvitamin D3 (Lehmann et al, 1995).
Calcipotriene ointment has been shown to absorb UV light in
the UVC and UVB ranges (Kornreich et al, 1995). As psoriasis pa-
tients are treated with several forms of UV light as well as topical
therapy, we decided to examine the impact of UV irradiation on
topical calcitriol, and the e¡ect of calcitriol ointment on the
transmission of UV light.
MATERIALS ANDMETHODS
Two grams of calcitriol 3 mg per g ointment was applied over a 40 cm2 area
and irradiated with 100 mJ per cm2 of broadband UVB, 3.0 J per cm2 of
narrowband UVB, or 10 J per cm2 of UVA.The light source for broadband
UVB consisted of eight FS72 T12-UVB-HO bulbs. The UVA light source
contained 36 F72 T12-BLHO bulbs, and the narrowband UVB source was
a Phototherapeutics phototherapy unit containing 32 Philips TL01 bulbs.
Control samples were exposed for 10 min to ambient light and £uorescent
light bulbs.
Following irradiation, ointment was removed with a wooden spatula
and placed in vials protected from light.
Apparatus Calcitriol and its related substances were assayed on a high
performance liquid chromatography system including a Merck-Hitachi
(Tokyo, Japan) pump model L6200A, a Waters (Milford, MA)
autosampler model 717þ, a Waters detector model 2487, an Alltech
(Deer¢eld, IL) column heater model 530, and a PC terminal equipped
withWaters Millennium 3.05.01 acquisition software.
Chemicals Calcitriol analytical reference standard was supplied by
Solvay Pharmaceuticals (Weesp,The Netherlands).
Dichloromethane (HPLC grade) and iso-octane (analytical grade) were
purchased from Merck (Darmstad, Germany) and 2-ethoxyethanol
(analytical grade) was obtained from Fluka (Buchs, Switzerland).
Procedure The liquid chromatograph was equipped with a 265 nm
detector and a 4.6 mm 250 mm Hypersil Si 5 mm column (Supelco,
Bellefonte, PA) with a 310 mm Si Aquapore 5 mm precolumn
(Alltech). The column temperature was maintained at 301C. The mobile
phase consisted of a mixture of dichloromethane, 2-ethoxyethanol, and
iso-octane (275:45:680). The £ow rate was 1.5 ml per min.
Sample preparations with a ¢nal calcitriol concentration of 0.48 mm per
ml were obtained by dispersing an accurately weighed amount of ointment
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into the mobile phase at 701C for 10 min. A portion of the dispersion was
centrifuged at 4000 rpm for 20 min and the clear supernatant was used for
chromatography.
Standard preparations with a ¢nal calcitriol concentration of 0.48 mm per
ml were obtained by dissolving an accurately weighed amount of calcitriol
analytical reference standard into the mobile phase.
Equal volumes (200 mL) of the standard and sample preparations were
separately injected into the chromatograph and the heights and areas of
the calcitriol, precalcitriol, and trans-calcitriol peaks were measured.
The content in mg per g of calcitriol, including precalcitriol, was
calculated using the formula
Isa1  ð f1Isa2Þ
 
mstVsa1000
Ist1msaVst
in which Isa1 and Isa2 are the peak heights of calcitriol and precalcitriol,
respectively, in the sample chromatogram, f1 is the conversion factor of
precalcitriol (2.23 the ratio of the retention times of precalcitriol and
calcitriol), Ist1 is the peak height of calcitriol in the standard chromatogram,
msa is the weighed amount of ointment in grams, mst is the weighed
amount of calcitriol analytical reference standard in milligrams,Vsa andVst
are the dilution volumes in milliliters of the sample preparation and of the
standard preparation, respectively, and 1000 is a factor to convert
milligrams into micrograms.
The content in mg per g of trans-calcitriol was calculated using the
formula
Isa3mstVsa1000
Ist2msaVst f2
in which Isa3 is the peak area of trans-calcitriol in the sample chromatogram,
Ist2 is the peak area of calcitriol in the standard chromatogram, and f2 is the
relative response factor of trans-calcitriol (¼1.25).
The e¡ect of calcitriol on transmission of UVA and UVB was also
assessed. Two grams of calcitriol 3 mg per g ointment was applied over a
40 cm2 area of a clear ¢lm that allows transmission of UV (SaranWrap)
to create a thin ¢lm of calcitriol ointment. Four grams of calcitriol 3 mg
per g ointment was applied over a 40 cm2 area of the clear ¢lm to create a
thick ¢lm of the ointment. The ¢lm with and without the two layers of
calcitriol was held between UV bulbs and a spectroradiometer to quantify
transmission of broadband UVB, narrowband UVB, and UVA. The light
sources mentioned above were used. Transmission of UV light was
recorded as a percentage of light transmitted through the ¢lm. According
to previously published methods, transmission of UVB and UVA through
both thin and thick layers of calcitriol ointment and vehicle was measured
by a spectroradiometer (Lebwohl et al, 1995).
RESULTS
All three forms of UV light tested, which are used to treat psor-
iasis patients, resulted in degradation of over 90% of calcitriol
(Table I).
UVA irradiation resulted in degradation of more than 98% of
calcitriol. Broadband UVB irradiation resulted in degradation
of 93% of calcitriol, and narrowband UVB reduced calcitriol to
undetectable levels. In comparison, following exposure to am-
bient light and £uorescent light, there was no signi¢cant loss of
calcitriol.
Thin layers of calcitriol ointment resulted in reduced transmis-
sion of UVA and markedly reduced transmission of UVB. The
vehicle produced similar reductions in transmission of UVA and
UVB. Thick layers of calcitriol ointment or vehicle resulted
in even greater reductions of transmission of UVA and UVB
(Table II).
DISCUSSION
This study demonstrates similar e¡ects of UVA, UVB, and nar-
rowband UVB on calcitriol. All three light sources resulted in
signi¢cant degradation of calcitriol. In addition, thin layers of
calcitriol ointment do not signi¢cantly block transmission of
UVA; application of thick layers of the ointment, however, may
block both forms of UV light. Although studies examining the
e⁄cacy of calcitriol ointment in combination with UVB, nar-
rowband UVB, and PUVA are warranted, the results of this
study suggest that calcitriol ointment should be applied follow-
ing phototherapy, not immediately before.
At the time this study was performed, an application for an
investigational new drug had not been ¢led for calcitriol oint-
ment, and clinical studies could therefore not be performed. Ap-
plying in vitro data to clinical situations has signi¢cant limitations.
Although calcitriol is degraded, it is always possible that degrada-
tion products might be active against psoriasis, and only clinical
testing can absolutely refute or support the latter possibility.
Moreover, other factors such as pH of the skin or skin surface
temperature might a¡ect degradation of calcitriol upon exposure
to UV light. Again, these studies could not be performed because
an application for an investigational new drug had not been ¢led.
Both the observed instability of calcitriol when exposed to UV
light sources and the reduction of UV transmission due to the
vehicle would indicate that, if used in conjunction with photo-
therapy, this product should be applied after irradiation, not be-
fore. These observations should be con¢rmed by clinical trials,
however.
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Table I. Degradation of calcitriol by UV light
UV source Residual calcitriol
Broadband UVB 6.7%
Narrowband UVB Not detected
UVA 1.5%
Control 100.3%
Table II. E¡ect of calcitriol ointment on UV transmission
UVA UVB
Thin layer vehicle 17% 67%
Thick layer vehicle 41% 87%
Thin layer calcitriol ointment 17% 50%
Thick layer calcitriol ointment 31% 83%
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